WO2004054598A1 - Use of plant extract of the family of clusiaceae for preparing a composition for treating or preventing greasy skin-mediated disorders - Google Patents

Use of plant extract of the family of clusiaceae for preparing a composition for treating or preventing greasy skin-mediated disorders Download PDF

Info

Publication number
WO2004054598A1
WO2004054598A1 PCT/FR2003/003704 FR0303704W WO2004054598A1 WO 2004054598 A1 WO2004054598 A1 WO 2004054598A1 FR 0303704 W FR0303704 W FR 0303704W WO 2004054598 A1 WO2004054598 A1 WO 2004054598A1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
composition
extract
plants
clusiaceae
family
Prior art date
Application number
PCT/FR2003/003704
Other languages
French (fr)
Inventor
Gilles Rubinstenn
Lionel Breton
Original Assignee
L'oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/008Preparations for oily skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/38Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/96Cosmetics or similar toilet preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toilet preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/12Preparations containing hair conditioners

Abstract

The invention concerns the use of plant extract of the family of clusiaceae for preparing a composition for reducing sebum secretion, and in particular for treating or preventing disorders associated with greasy skin. The invention concerns particularly cosmetic compositions for oral or topical administration for reducing sebum secretion. The invention also concerns a cosmetic method for reducing sebum secretion, and in particular for treating or preventing disorders associated with hyperseborrhea.

Description

USE OF AN EXTRACT OF PLANT FAMILY

Clusiaceae IN THE PREPARATION OF A COMPOSITION

FOR CORRECT OR PREVENT DISORDERS ASSOCIATED

AN OILY

The present invention relates to the use of an extract of plants of the family Clusiaceae in the preparation of a composition intended to correct or prevent disorders associated with oily skin in particular by an action of decreasing the secretion of sebum. The invention aims in particular cosmetic compositions for oral or topical administration. The invention also relates to a cosmetic method for correcting or preventing disorders associated with hyperséborr ed.

A hyperseborrhoeic greasy skin is characterized by secretion and excretion of sebum. Conventionally, a sebum level greater than 200 g / cm2 measured on the forehead is considered to be characteristic of such oily skin.

Oily skin is often associated with a desquamation defect, shiny complexion, a thick skin texture.

In addition to these aesthetic disorders, excess oil can provide support to the anarchic development of bacterial flora saprophyte

(P. Acnes in particular) and cause blackheads and / or acne lesions.

Sebum is the natural product of the sebaceous gland which is an annex of the pilosebaceous unit. It is basically a mixture more or less complex lipids. Conventionally, the sebaceous gland produces squalene, triglycerides, aliphatic waxes, cholesterol waxes and possibly free cholesterol (Stewart.ME, Semin Dermatol 11, 100-105 (1992)). The action of bacterial lipases converts a variable portion of the triglycerides, free fatty acids formed.

The sebocytes are the competent cells of the sebaceous gland. Sebum production is associated with terminal differentiation program that cell. During this differentiation, the metabolic activity of sebocytes is mainly focused on the biosynthesis of lipids (lipogenesis) and more specifically on the fatty acid neosynthesis.

The sebaceous secretion is under the control of different afferents of nervous origin. . In particular, Cartlidge M. et al (Br J Dermatol 1972;

86 (1), 61-63) indicated the modulatory role of the cholinergic system (para-lymphatic) on seborrhea.

This secretion is also under endocrine control since the plaintiff has shown a negative regulatory activity of cortisol on the sebaceous secretion.

This séborégulatrice cortisol activity demonstrated experimentally on sebocytes in culture confirms the work of Leveque et al. (Arch Dermatol Res 283, 372-6, (1991)) on the control hyperseborrhoeic condition by topical application of glucocorticoids.

He described elsewhere, that cortisol secretion is particularly dependent of the serotonin system. So there is a relationship between the nervous system, endocrine system and seborrhea. This cortisol production is under the specific dependence of the 5HT4 serotonin receptor (Lefebvre et al., Neurosci. 47, 999-1007 (1992)).

The serotonin system is a major aminergic systems involved in neurotransmission. In addition, oral administration of a serotonin reuptake inhibitor (such as citalopram) whose role is to increase the concentration of intra-synaptic serotonin, increases blood levels of cortisol (Seifritz et al. J. Psychiatr. Res. 31, 543-4 (1992)).

The invention results from the discovery that a composition comprising an extract of St. John's wort has activity on hyperseborrhoea. The invention further stems from the observation that an inhibitory activity on the reuptake of serotonin observed in a Hypericum perforatum extract may have a beneficial effect on the treatment or prevention of skin disorders associated with hyperseborrhoea.

St. John's Wort (Hypericum perforatum) is part of the family Clusiaceae.

This perennial herb, very common in uncultivated places and roadsides of Europe and I "in North America, has erect stems and rowers, wearing small opposite and sessile leaves, not specified (1-2, 5 x 0.5-1 .5 cm). The leaf blade, dark green, is dotted with transparent punctuation (secretory schizogènes pockets) and lined with small black dots (cell clusters invaded by pigments). The flowers, grouped in clusters corymbiform are easily recognizable by their slightly asymmetrical 5 yellow petals, their numerous stamens fused into 3 bundles and their 3 styles overcoming divergent dark red carpels 3. The fruit is a capsule opening with 3 valves.

The plant provides about 0.6 to 3 ml / kg of essential oil (terpene hydrocarbons, 2-methyloctane, n-alkanols, etc.), triterpenes and sterols. It is rich in phenolic compounds: caffeic acid, chlorogenic acid, proanthocyanidins (oligomers of catechin and epicatechin), prenylated derivatives of phloroglucinol (found in flowers and fruits where they concentrate at maturity: hyperforin [2-4 , 5%], adhyperforine [0,2-1, 8%]) and flavonoids. These are abundant (2-4%): hyperoside, rutin, and Quercitrin isoquercitroside and concentrated in the flowers, bisflavones.

The constituents responsible for the coloration of juice contained within the punctuations blackish leaves and flowers are naphtodianthrones (from 0.06 to 15%): hypericin, biogenetically derived from émodol anthrone, is accompanied pseudohypericin and, the fresh plant, and the protohypericin protopseudohypéricine.

The Hypericum perforatum is reputed healing. The antibacterial properties of Hypericum perforatum extracts have been demonstrated in vitro.

Moreover, the tests normally used in animals to detect antidepressant activity show that St. John's wort

(Hypericum perforatum) has a stimulating effect on the central nervous system. This activity is classically described as induced MAOIs like activity.

Over fifteen different active substances were thus isolated from the wort. Among them, the most important seem to be hypericin, pseudohypericin, hyperforin, phenylated derivatives of phloroglucinol, hyperoside, flavonoids and tannins.

Hypericin is regarded as the essential active ingredient of anti-depressive effect of extracts of St. John's wort.

However, since no effect was confirmed by a single hypericin administration, the question arises of the additional potential role of other active ingredients of the plant in the antidepressant activity of the extract of St. John's wort.

To the knowledge of the Applicant, it has never been suggested to use an extract of St. John's wort, and more generally to plants of the family Clusiaceae in the preparation of a composition for correcting or preventing disorders associated with oily skin, in particular by an action leading to decrease sebum secretion.

The invention therefore relates to the use of an extract of the family Clusiaceae plants in the preparation of a composition intended for treating greasy skin.

The observed activity of improving the condition of oily skin as a result of treatment, may especially result from the decrease in the secretion of sebum. The production of sebum at the skin may be determined by measuring the sebum level according to the method described by JL Leveque in patent FR 2,968,708.

By "reduced secretion of sebum" means a significant reduction of sebum in the skin, that is to say at least 10%, preferably at least 30% of sebum.

The species of Clusiaceae selected for preparation of plant extracts used in the compositions are preferably chosen among the species of the genus Hypericum.

Particular examples are the species Hypericum perforatum.

In a particular embodiment, the extract is from the St. John's wort

(Hypericum perforatum). The extract can be obtained from the aerial parts of the plant, including leaves, flowers, fruit, or seed or any other part of the plant. Preferably, the extract is obtained from the flower.

containing extracts is advantageously used hypericin and / or hyperforin which can be prepared according to the numerous methods described in the prior art. Complete solids or dried wort extracts enriched in hyperforin include obtainable by the process described in EP-A-0599307.

The inhibitory effect of serotonin reuptake present in the extract of plants used according to the invention may in particular be determined by measuring the percentage of serotonin reuptake as described by Marcusson et al. (Neurochem 50: 1783-1790).

The extract is preferably obtained so as to have an inhibitory effect on serotonin reuptake greater than or equal to that present in the plant before extraction.

In particular, an extract of the Clusiaceae family of plants can be obtained by an aqueous extraction, alcoholic or aqueous-alcoholic, and preferably with an alcoholic extract or hydro-alcoholic.

The invention also relates to compositions comprising the extract of plants of the family Clusiaceae, for correcting or preventing disorders associated with oily skin, in particular by an action of decreasing the secretion of sebum. The proportion of plant extract in the composition is of course determined by the desired effect on the inhibition of sebaceous function of the skin and the mode of administration of the composition. In a particularly preferred embodiment, the composition is formulated for oral administration. In this case, it may be in any dosage form suitable for this mode of administration, for example in the form of divisible tablets or not, granules, capsules, capsules, solutions, suspensions or solutions comprising a suitable excipient.

Preferably, a composition of the invention is a nutritional supplement, presented in the form of a solid composition, type of tablets, granules, capsules and comprising a plant extract as defined above and a suitable adjuvant for oral administration.

In this respect, adjuvants for oral compositions, including food supplements, are known to the skilled artisan. There may be mentioned, among others, and purely illustratively, lubricants such as magnesium stearate, products for instant solubilizing agents, gelling agents, thickeners, humectants, fatty and / or aqueous components, preservatives, texturing agents, flavoring agents and / or coating agents, antioxidants and dyes that are customary in the food industry.

The composition according to the present invention may further comprise one or more vitamins and / or trace elements. As such, for example, can be used alone or in combination the following assets: zinc and its salts, sulphate and zinc glucanate, vitamins B5, B6, B8, C, E or PP, β-carotene and carotenoids, garlic extracts, in particular in the form of allyl sulfide or Ajoen, selenium, curcumin, curcuminoids, niacin, lithospermic acid and adenosine. It is understood that the skilled person will choose such assets and, where applicable, will combine in order to improve the expected effects of the composition according to the invention, by preventing the activity of interest sought to be inhibited or alleviated. The composition for oral administration comprising an extract of plants of the family Clusiaceae in an amount ranging from 0.001% to 40% by weight of the composition, preferably from 0.05% to 5% by weight and more preferably from 0.1% to 1% by weight of the composition.

The invention also relates to a cosmetic process for treating greasy skin, for the prevention and / or treatment of skin disorders associated with hyperseborrhoea, and in particular acne lesions, comprising administering orally a composition comprising an extract of plants of the family Clusiaceae, and in particular an extract of St. John's wort (Hypericum perforatum), as described above.

Daily doses of extract of plants of the family Clusiaceae administered orally for the treatment of oily skin may be between 1 and 5000 mg / day, preferably. Preferably, the extract of plants of the family Clusiaceae is included in the composition according to the invention in an amount allowing its administration at a dose between 5 and 1000 mg / day, said dosage being carried out in one or more administrations.

According to another embodiment, the composition comprising an extract of plants of the family Clusiaceae is formulated for topical administration. In this case, the plant extract may be present in the composition in an amount ranging from 0.0001 to 20% by weight, and preferably from 0.001 to 10%.

A composition formulated for topical administration according to the invention contains a cosmetically or dermatologically acceptable medium, that is to say a medium compatible with the skin, nails, mucous membranes, tissues and the hair. According to a preferred embodiment of the invention, the composition has a pH preferably close to that of the skin, between 4 and 7. The composition comprising an extract of plants of the family Clusiaceae is preferably applied topically on the face, neck, hair, mucous membranes and the nails or any other cutaneous region of the body.

A cosmetic composition according to the invention may be in any galenic forms normally used in cosmetic and dermatological fields. It can be especially in the form of alcoholic or oily solutions, dispersions of lotion or serum type, of anhydrous or oily gels, of emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersing a fatty phase in an aqueous phase (O / W) or conversely (W / O), or a triple emulsion (W / O / W or O / EH), suspensions or emulsions of soft, semi-solid or solid consistency of the type cream, gel, microemulsions, or microcapsules, of microparticles or of vesicular dispersions of ionic and / or nonionic surfactant. These compositions are prepared by conventional methods.

The compositions of the invention may also be used for the hair in the form of alcoholic or aqueous solutions, or in the form of creams, gels, emulsions, foams.

The amounts of the various constituents of the compositions used according to the invention are those conventionally used in the fields considered.

These compositions constitute protective creams, treatment or care for the face, hands or body, body milks for protection or care, lotions, gels or foams for care of the skin and mucous membranes or for cleaning the skin. The compositions can also consist of solid preparations constituting soaps or cleansing bars.

In known manner, the composition used according to the invention may also contain adjuvants commonly used in cosmetics and dermatology, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, fragrances, fillers and coloring materials. The amounts of these various adjuvants are those conventionally used in the fields under consideration, and for example from 0.01% to 20% of the total weight of the composition. Of course, the man of the art care to select this or these optional additives and / or the amounts thereof such that the advantageous properties intrinsically associated with the composition are in accordance with the invention, particularly inhibitor activity this serotonin in the plant extract of the family Clusiaceae, are not, or not substantially, impaired by the envisaged addition.

As oils used in the invention, mineral oils there may be mentioned (liquid paraffin), vegetable oils (arity oil, sweet almond oil), animal oils, synthetic oils, silicone oils (cyclomethicone) and fluorinated oils (perfluoropolyethers). Can also be used as fatty substances, fatty alcohols, fatty acids (stearic acid) and waxes (paraffin, carnauba, beeswax).

As emulsifiers used in the invention include polysorbate 60 and sorbitan stearate sold respectively under the trade names Tween 60 and Span 60 by ICI. co-emulsifiers can be added such as PPG-3 myristyl ether sold under the trade name Emcol 249-3K spoke Witco. As solvents used in the invention include the lower alcohols, especially ethanol and isopropanol, and propylene glycol.

As hydrophilic gelling agents, mention may be made of carboxyvinyl polymers (carbomer), acrylic copolymers such as acrylate / alkylacrylate copolymers, polyacrylamides, polysaccharides such as hydroxypropylcellulose, natural gums (xanthan) and clays, and, as lipophilic gelling agents, there may be mentioned modified clays such as bentones, metal salts of fatty acids such as aluminum stearates, hydrophobic silica, polyethylenes and ethyl cellulose.

As hydrophilic active agents, use may be proteins or protein hydrolysates, amino acids, polyols, urea, allantoin, sugars and sugar derivatives, water-soluble vitamins, starch, bacterial extracts or plants including Aloe Vera.

As lipophilic active, you can use tocopherol (vitamin E) and its derivatives, essential fatty acids, ceramides and essential oils.

In order to fight effectively against photoaging, it is further possible to add to the composition used according to the invention one or more complementary sun filters active in the UVA and / or UVB, hydrophilic or lyophilic optionally comprising a function sulfonic acid.

The sunscreen is preferably selected from organic filters and / or mineral filters.

As organic screening agents, mention may be made of cinnamic derivatives, salicylic derivatives, camphor derivatives, triazine derivatives, benzophenone derivatives, dibenzoylmethane derivatives, the β derivatives, β-diphenylacrylate derivatives p-aminobenzoic acid derivatives, screening polymers and screening silicones described in application WO-93/04665 or organic screening agents described in patent application EP-A 0,487,404.

As mineral filters, there may be mentioned pigments or nanopigments (mean size of primary particles: generally between 5 nm and 10 nm, preferably between 10 and 50 nm) of metal oxides, coated or not, such as nanopigments titanium oxide (amorphous or crystallized in rutile and / or anatase form), iron, zinc, zirconium or cerium oxide, which are all photoprotective agents well known per se, acting by physically blocking

(Reflection and / or scattering) UV radiation. Standard coating agents are, moreover, alumina and / or aluminum stearate. Such nanopigments of metal oxides, coated or uncoated, are in particular described in patent applications EP-A-0518772 and EP-A-0518773.

Examples of solar complementary active in the UV-A and / or UV-B range include: p-aminobenzoic acid, p-aminobenzoate oxyethylenated (25 mol), p-dimethylaminobenzoate 2- ethylhexyl acrylate, ethyl p-aminobenzoate N-oxypropylenated, glyceryl p-aminobenzoate, homomenthyl salicylate, salicylate, 2-ethylhexyl, triethanolamine salicylate, 4-isopropylbenzyl, 4-ter- butyl-4'-methoxy-dibenzoylmethane (Parsol 1789 from Givaudan

Roure) p-methoxycinnamate, 2-ethylhexyl (PARSOL MCX from Givaudan

Roure) 4-isopropyl-dibenzoylmethane (Eusolex 8020 from Merck), menthyl anthranilate, 2-ethylhexyl-2-cyano-3,3'-diphenylacrylate (Uvinul N539 BASF), the ethyl-2- cyano-3,3'-diphenylacrylate, 2-phenyl benzimidazole 5-sulphonic acid and its salts, 3- (4'-trimethylammonium) -benzylidèn-bornan-2-one-methyl, 2-hydroxy-4- methoxybenzophenone (Uvinul MS 40 from BASF), 2-hydroxy-4-methoxybenzophenone-5-sulfonate (Uvinul MS 40

BASF), 2,4-dihydroxybenzophenone (UVINUL 400 BASF), 2,2 ', 4,4'-tetrahydroxy benzophenone (Uvinul D 50 from BASF), 2,2'-dihydroxy-4,4'-dimethoxybenzophenone (Helisorb NORQUAY II), 2-hydroxy-4-n-octoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, the α- (2-oxoborn-3-ylidene) tolyl-4 sulfonic acid and its salts, 3- (4'-sulfo) benzylidèn-boman-2-one and its salts, 3- (4'-methylbenzylidene) -d, l-camphor, 3-benzylidene-d, l camphor, benzene-1, 4-di (3-methylidene-10-camphorsulphonic acid) and its salts

(Mexoryl SX from Chimex), urocanic acid, 2,4-6-tris [p- (2'-ethylhexyl-1 '-oxycarbonyl) anilino] -1, 3,5-triazine, 2- [ p- (tert-butylamido) anilino] -4,6-bis [p- (2'-ethylhexyl-1 '- oxycarbonyl) anilino] -1, 3,5-triazine, 2,4-bis *! [4-2-ethyl-hexyloxyl] -2-hydroxy-phenyl I - ^ - methoxy-phenyl) -

1, 3,5-triazine, the polymer of N- (2 and 4) - [2-oxoborn-3-yliden) methyl) benzyl] -acrylamide, 4,4-bis-benzimidazolyl phénylèn-3, 3 ', 5,5'-tetrasulphonic acid and its salts, 2,2'-méthylèn-bis- [6- (2H-benzotriazol-2-yl) -4- (1, 1, 3,3-tetramethylbutyl) phenol ], polyorganosiloxanes function malonate.

The invention also relates to a cosmetic treatment method, by applying the compositions as defined above according to the usual technique for using these compositions. For example: application of creams, gels, serums, ointments, lotions or milks to the skin, scalp, nails and / or mucous membranes.

The invention particularly relates to a cosmetic method for the treatment and / or prevention of skin disorders associated with hyperseborrhoea, in particular for the treatment and / or prevention of acne lesions, comprising applying to the skin, mucous membranes and / or the keratin fibers a composition comprising an extract of plants of the family Clusiaceae.

The characteristics of the invention mentioned above, as well as others, will become more apparent in light of the following examples.

EXAMPLES

example 1

Activity of an extract of Hypericum perforatum on the reuptake of serotonin:

It has been shown, in a study on different pharmacological targets that Hypericum altered reuptake several brain biogenic amines (noradrenaline, dopamine, serotonin).

The results are summarized in the table below:

Figure imgf000016_0001

These results are in reuptake inhibition percentage.

They show that the extract of Hypericum perforatum is an inhibitor of mixed reuptake including it influences serotonin reuptake therefore it increases the bioavailability of serotonin intrasynaptique.

example 2

Preparation of a hydroalcoholic extract of Hypericum perforatum flowering somites 400 g Hypericum perforatum dried are pulverized by grinding with a Turrax at 20 000 t / min for 3 minutes at 4 ° C (in an ice bath) .

The powder thus obtained is mixed with 4 liters of a mixture 80: 20 Buffer 0.05 M phosphate: absolute ethanol. The mixture is stirred for

1 h at 4 ° C, then centrifuged at 10,000 G at 4 ° C. The supernatant is then filtered at 0.22 microns for sterilization.

The extract thus obtained is fractionated by ultrafiltration on Sartorius type membrane in order to eliminate oxidation phenomena. The extract is then used in the state or lyophilized for approximately

15 g of active extract termed "freeze-dried extract."

example 3

Dragees for oral absorption

Active ingredients mg / coated tablet extract of Hypericum perforatum 300

Excipient of the core of the coated tablet

mino-crystalline cellulose 70

Encompress ™ 60 Magnesium Stearate 3

anhydrous colloidal silica 1

Coating agent

Shellac 5

Talc 61 Polyvidone 6

This type of lozenge can be taken 1 to 4 times per day. Example 4: Capsules for oral absorption mg / capsule Active Ingredients

Extract of Hypericum perforatum 200 Borage Oil 200

blackcurrant seed oil 200

vitamins

Vitamin C 60

Vitamin E 2

Example 5: lotion for the scalp

Hypericum perforatum extract 5.00%

3.00% antioxidant

Isopropanol 40.00%

Preservative 2.00% Water qs 100.00%

Example 6: Care cream (oil in water emulsion)

lyophilized extract of Hypericum perforatum 5.00%

glyceryl stearate 2.00%

Polysorbate 60 (Tween 60 ® sold by ICI) 1 00% Stearic Acid 2.00%

Triethanolamine 0.80%

Carbomer 0.40%

Liquid fraction of shea butter 12,00%

Perhydrosqualene 12.00% Antioxidant 2.00%

Water to 100.00%

Claims

1. Composition suitable for the treatment of greasy skin comprising an extract of plant of the family Clusiaceae.
2. Composition according to claim 1, wherein the extract of plant of the family Clusiaceae decreases the secretion of sebum.
3. Composition according to any one of claims 1 to 2, wherein the extract is obtained from plants of the genus Hypericum, preferably St John's wort (Hypericum perforatum).
4. Composition according to any one of claims 1 to 3, wherein the extract is obtained by aqueous extraction, alcoholic or hydro-alcoholic.
5. Composition according to any one of claims 1 to 4, wherein the extract is obtained by an alcoholic or aqueous-alcoholic extraction.
6. Composition according to any one of claims 1 to 5 formulated for oral administration.
7. The composition of claim 6, wherein the extract of plants of the family Clusiaceae represents from 0.001 to 40% by total weight of the composition.
8. Composition according to claim 7, wherein the plant seed extract represents from 0.05% to 5%, preferably from 0.1% to 1% by total weight of the composition.
9. Composition according to any one of claims 1 to 5, formulated for topical administration.
10. The composition of claim 9, wherein the extract of plants of the family Clusiaceae represents from 0.0001 to 20% by total weight of the composition.
11. The composition of claim 10, wherein the extract of plants of the family Clusiaceae represents from 0.001 to 10% by total weight of the composition.
12. Composition according to any one of claims 1 to 11, for correcting disorders associated with hyperseborrhoea, and in particular to treat and / or prevent acne lesions.
13. Cosmetic process for treating greasy skin, for the prevention and or treatment of acne lesions, comprising applying to the skin, mucous membranes or keratinous fibers and a composition comprising an extract of plants of the family Clusiaceae.
14. Cosmetic process for treating greasy skin, for the prevention and / or treatment of acne lesions, comprising administering orally a composition comprising an extract of plants of the family Clusiaceae.
15. Use of an extract of plants of the family Clusiaceae for the preparation of a composition for treating greasy skin.
16. Use according to claim 15, in that the plant extract is obtained from plants of the genus Hypericum.
17. Use according to claim 15, in that the plant extract is obtained from Hypericum plants. 04/054598
20
18. Use according to any one of claims 15 to 17, formulated for oral administration or for topical administration.
19. Use according to any one of claims 15 to 18 for the preparation of a composition intended to correct disorders associated with hyperseborrhoea.
20. Use according to any one of claims 15 to 19 for the preparation of a composition for the prevention and / or treatment of acne lesions.
PCT/FR2003/003704 2002-12-13 2003-12-12 Use of plant extract of the family of clusiaceae for preparing a composition for treating or preventing greasy skin-mediated disorders WO2004054598A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR02/15868 2002-12-13
FR0215868A FR2848455B1 (en) 2002-12-13 2002-12-13 Use of an extract of plants of the family Clusiaceae in the preparation of a composition destinee to correct or prevent the disorders associated with oily skin
US44173503 true 2003-01-23 2003-01-23
US60/441,735 2003-01-23

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2003300594A AU2003300594A1 (en) 2002-12-13 2003-12-12 Use of plant extract of the family of clusiaceae for preparing a composition for treating or preventing greasy skin-mediated disorders

Publications (1)

Publication Number Publication Date
WO2004054598A1 true true WO2004054598A1 (en) 2004-07-01

Family

ID=32598897

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/003704 WO2004054598A1 (en) 2002-12-13 2003-12-12 Use of plant extract of the family of clusiaceae for preparing a composition for treating or preventing greasy skin-mediated disorders

Country Status (1)

Country Link
WO (1) WO2004054598A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2570277A1 (en) * 1982-10-07 1986-03-21 Delta Vas Mueanyag Szolgaltato cosmetic compositions for the post-treatment of seborrheic acneiform process and a process for preparing the
US6238671B1 (en) * 1998-04-22 2001-05-29 Bionorica Arzneimittel Gmbh Process for the gentle recovery of extract fractions from hypericum, pharmaceutical preparations containing the same and their use
DE10131641A1 (en) * 2000-12-22 2002-06-27 Schwabe Willmar Gmbh & Co St. John's wort extracts having reduced chlorophyll and proanthocyanidin contents, useful as topical medicaments, e.g. for treating stomatitis, acne, viral infections or psoriasis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2570277A1 (en) * 1982-10-07 1986-03-21 Delta Vas Mueanyag Szolgaltato cosmetic compositions for the post-treatment of seborrheic acneiform process and a process for preparing the
US6238671B1 (en) * 1998-04-22 2001-05-29 Bionorica Arzneimittel Gmbh Process for the gentle recovery of extract fractions from hypericum, pharmaceutical preparations containing the same and their use
DE10131641A1 (en) * 2000-12-22 2002-06-27 Schwabe Willmar Gmbh & Co St. John's wort extracts having reduced chlorophyll and proanthocyanidin contents, useful as topical medicaments, e.g. for treating stomatitis, acne, viral infections or psoriasis

Similar Documents

Publication Publication Date Title
US5710177A (en) Synergistic combinations of active substance for the cosmetic or dermatological care of the skin, hair & nails
US6376557B1 (en) Methods for treating alopecia
US20080069898A1 (en) Topical Compositions Comprising Myrica Gale Oil
WO2005041996A1 (en) Lotus and methyl donors
US5869063A (en) Dermatological and cosmetic compositions containing marama bean extract
JPH07278003A (en) Testosterone-5alpha-reductase inhibitor
WO2008009709A1 (en) Use of a rice protein hydrolysate as pigmenting active principle
US20050244360A1 (en) Cosmetic composition for greasy skin care, containing a carboxylic fatty acid or a derivative thereof
JP2000169383A (en) Antiallergic agent
US20050255077A1 (en) Skin-smoothing cosmetic based on plant extracts
US20030199446A1 (en) Use of ectoin or ectoin derivatives for stabilizing p53
US20100119463A1 (en) Antioxidant compositions for the cleansing and conditioning of skin
JP2004123563A (en) Cosmetic containing fruit oil obtained from hippophae and ingredients extracted from other galenicals
US6068845A (en) Inhibition of abnormal accumulation of extra-cellular matrices
US20090137534A1 (en) Skin treatment compositions and methods
JP2000247829A (en) Cosmetic, unregulated drug, medicine and food
US20040234632A1 (en) Use of at least an oil extracted from the seeds of the gourd family for preparing a composition for inhibiting 5$g(a)-reductase activity
JP2002316937A (en) Plant extract-containing anti-allergic agent
JPH0717845A (en) Skin external preparation
US20080171031A1 (en) Compositions for Juice-Based Moisturizers
JPH09227353A (en) Skin whitening cosmetic composition
US20010012524A1 (en) Anti-aging agent
US20070207228A1 (en) Composition for Regulating the Trophism of Hair Follicles and the Cutaneous Production of Sebum and Use Thereof in Androgenic Alopecia
US20070274937A1 (en) Use of a Cruciferous Protein Hydrolysate as a Depigmentation Agent or For a Cosmetic and/or Pharmaceutical Composition
US20080166314A1 (en) Compositions for juice-based treatment serums

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP